Novartis eyes Rhapsido’s broader use on positive urticaria data drop
Novartis’ marketed therapy, Rhapsido (remibrutinib), has been shown to offer rapid and durable impacts on various subtypes of chronic induced…
Novartis’ marketed therapy, Rhapsido (remibrutinib), has been shown to offer rapid and durable impacts on various subtypes of chronic induced…
Amgen’s experimental drug, dazodalipeb, has demonstrated its potential as an effective first-in-class option for the treatment of Sjögren's disease, as…
Johnson & Johnson’s (J&J’s) $14.6bn acquisition of CNS-focused biotech, Intra-Cellular Therapies, is looking increasingly well placed, as the company is…
On 4 November, the Democrats made history by winning the Senate and the House in the US midterm elections –…
Faeth Therapeutics’ cancer combination has improved outcomes in patients with advanced endometrial cancer in a Phase II trial – potentially…
Gilead Sciences’ primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), has been shown to diminish a key marker of disease activity…
Gan & Lee Pharmaceuticals’ long-acting obesity therapy bofanglutide has been shown to maintain weight loss when reduced to a once-monthly…
In recent years, the biotech financing landscape has been in a period of tumult, with ever-growing competition and shifts in…
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has debuted guidance laying out best practices for submitting unconventional non-clinical…
The Democrats have gained significantly more power to contest the Trump administration’s healthcare agenda after the party won the Senate…